These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 35868896)

  • 1. Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline.
    Patoulias D; Dimosiari A; Michailidis T; Roditis P; Lampropoulos S
    Am J Cardiol; 2022 Sep; 179():116-117. PubMed ID: 35868896
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.
    Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Jul; 174():188-189. PubMed ID: 35550822
    [No Abstract]   [Full Text] [Related]  

  • 3. First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.
    Dziewięcka E; Winiarczyk M; Gliniak M; Kaciczak M; Wiśniowska-Śmiałek S; Karabinowska A; Holcman K; Kostkiewicz M; Hlawaty M; Leśniak-Sobelga A; Podolec P; Rubiś P
    Cardiol J; 2020; 27(5):639-641. PubMed ID: 32789840
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Obes Metab; 2021 Apr; 23(4):1063-1065. PubMed ID: 33319468
    [No Abstract]   [Full Text] [Related]  

  • 5. Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.
    Patoulias D; Doumas M; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():169-170. PubMed ID: 35382927
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
    Qiu M; Zhou X; Zhang M
    Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer?
    Patoulias D; Kassimis G; Fragakis N
    Pharmacol Res; 2023 Jan; 187():106619. PubMed ID: 36535570
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?
    Patoulias D; Papadopoulos C; Doumas M
    Int J Cardiol; 2021 Jan; 323():259. PubMed ID: 32810546
    [No Abstract]   [Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Metab Syndr; 2020; 14(4):347. PubMed ID: 32305776
    [No Abstract]   [Full Text] [Related]  

  • 10. Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.
    Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Sep; 179():111-114. PubMed ID: 35871863
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs.
    Lim LL; Chan JCN
    Hong Kong Med J; 2019 Aug; 25(4):268-270. PubMed ID: 31416989
    [No Abstract]   [Full Text] [Related]  

  • 12. Sodium-glucose co-transporter type-2 inhibitors: is the message getting through? A reply.
    Nathanson M
    Anaesthesia; 2019 May; 74(5):680. PubMed ID: 30957885
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?
    Patoulias D; Katsimardou A; Kalogirou MS; Karagiannis A; Doumas M
    Dig Liver Dis; 2020 Feb; 52(2):239-240. PubMed ID: 31787555
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus.
    Yeggalam A; Liebich JA; Yu K; Shrestha E; Nadella S; Ahir V; Newman J; Lentine KL; Caliskan Y; Abu Al Rub F; Dhindsa S; Albert SG
    Diabetes Obes Metab; 2023 Jun; 25(6):1777-1780. PubMed ID: 36846956
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study.
    Patoulias D; Toumpourleka M; Katsimardou A; Zografou I; Stavropoulos K; Imprialos K; Karagiannis A; Doumas M; Papadopoulos C
    Kardiol Pol; 2022; 80(6):696-698. PubMed ID: 35445742
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
    Kalra S; Bhattacharya S; Kapoor N
    J Pak Med Assoc; 2022 May; 72(5):989-990. PubMed ID: 35713074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 inhibitors and hematopoiesis.
    Yaribeygi H; Maleki M; Nasimi F; Butler AE; Jamialahmadi T; Sahebkar A
    J Cell Physiol; 2022 Oct; 237(10):3778-3787. PubMed ID: 35951776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Griffin TP; Dinneen SF
    Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
    Giorgino F; Vora J; Fenici P; Solini A
    Diabetes Obes Metab; 2020 Sep; 22(9):1481-1495. PubMed ID: 32285611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
    Garla V; Subauste A; Butler J; Lien LF
    J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.